A round-table session held in 2020 during the 9th Conference of the European Hidradenitis Suppurativa Foundation in Athens concluded that targeting TNF-α and IL-12/23 results in better clinical outcomes in psoriasis than in psoriatic arthritis, HS, and Crohn’s disease, whereas targeting IL-17 is significantly more effective in psoriasis than in psoriatic arthritis, and it is obviously not effective in Crohn’s disease [193]. The gene discussed is IL17A; the disease is psoriasis.